论文部分内容阅读
从理论和临床上的初步结果均支持预后不良的非霍奇金淋巴瘤(NHL)病人应较早应用用自体骨髓移植(ABMT)治疗。作者对50例60岁以下至少达到一次CR 的中、高度恶性NHL 病人进行了预后因素分析,结果显示,诊断时有大块肿瘤病灶及/或血清LDH≥600U/L 者,其常规化疗的疗效欠佳,故作者把以上两个因素作为高危特征.并作为选择ABMT 治疗的条件。作者选择18例具有上述高危特征的病人进行ABMT 作为巩固治疗。移植时病情:CR_112例,CR_2或CR_(?)6例。预处理:Cy 60mg/kg×2、TBI10～12Gy。结果:中效随访35个月,总的无病生存率为65%,在CR_1和以后CR 期进行移植的病人之间没有明显差异。毒性死亡率11%。8/12例在CR_1期移植的病人仍存活,从CR_1后无病生存12～55个月。从ABMT 后为8～52个月,2例(17%)复发。
Both theoretical and clinical preliminary results support that patients with poor prognosis of non-Hodgkin lymphoma (NHL) should be treated with autologous bone marrow transplantation (ABMT) earlier. The authors analyzed prognostic factors in 50 patients with moderate-to-high-grade NHL who had achieved at least one CR after the age of 60. The results showed that there were large tumor lesions and/or serum LDH≥600 U/L at the time of diagnosis. Unsatisfactory, so the author takes the above two factors as high-risk features and as a condition for selecting ABMT treatment. The authors selected 18 patients with the above high-risk characteristics to undergo ABMT as a consolidation therapy. Condition of transplantation: CR_112 cases, CR_2 or CR_(?) 6 cases. Pretreatment: Cy 60 mg/kg×2, TBI 10-12 Gy. RESULTS: After a median follow-up of 35 months, the overall disease-free survival rate was 65%. There was no significant difference between patients who were transplanted between CR_1 and later CR. Toxic mortality rate 11%. 8/12 patients who were transplanted at the CR1 stage were still alive, and survived without CR-12 for 12 to 55 months. From 8 to 52 months after ABMT, 2 patients (17%) relapsed.